Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.39 |
| ▸ | PTGES | O14684 | 3/20 | 0.38 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235422 | 0.88 | CYP2D6 (0.49) | HRH4HRH3CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL614201 | 0.84 | FFAR1 (0.46) | FFAR1FFAR4PTGESHAO1 | |
| Trifluoroacetic Acid SCHEMBL613577 | 0.83 | CYP2D6 (0.41) | HRH3CYP2D6FFAR1FFAR4PTGES | |
| Trifluoroacetic Acid SCHEMBL610813 | 0.83 | PTGES (0.45) | FFAR1FFAR4PTGES | |
| Trifluoroacetic Acid SCHEMBL609882 | 0.83 | PTGES (0.45) | FFAR1FFAR4PTGES | |
| Trifluoroacetic Acid SCHEMBL611604 | 0.82 | FFAR1 (0.44) | FFAR1FFAR4PTGESPPARGPPARA | |
| SCHEMBL236313 | 0.80 | CYP2D6 (0.39) | HRH4HRH3CYP2D6PTGESHAO1 | |
| Trifluoroacetic Acid SCHEMBL612774 | 0.80 | FFAR1 (0.40) | FFAR1FFAR4PTGES | |
| Trifluoroacetic Acid SCHEMBL611293 | 0.80 | HTR2C (0.44) | HRH4HRH3FFAR1FFAR4 | |
| Trifluoroacetic Acid SCHEMBL613494 | 0.79 | FFAR1 (0.47) | FFAR1FFAR4PTGESHAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452153-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-9056849-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20140323530-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8716529-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8450527-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8076516-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2111223-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009058216-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | HRH4 364/4885HRH3 288/4885CYP2D6 3706/4885 |
| US-20140323530-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | HRH4 364/4885HRH3 288/4885CYP2D6 3706/4885 |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | HRH4 364/4885HRH3 288/4885CYP2D6 3706/4885 |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | HRH4 364/4885HRH3 288/4885CYP2D6 3706/4885 |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | PDE6D, CLN6, AADAT | HRH4 364/4885HRH3 288/4885CYP2D6 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.